Loading...
•
Jun 30, 2023
Journey Medical Q2 2023 Earnings Report
Reported a revenue increase driven by topline results from Phase 3 clinical trials and strategic initiatives.
Key Takeaways
Journey Medical Corporation reported a 41% increase in total net revenues, reaching $17.2 million in the second quarter of 2023 compared to $12.2 million in the first quarter. The company also announced positive topline results from two Phase 3 clinical trials evaluating DFD-29.
Total net revenues reached $17.2 million, a 41% increase from the previous quarter.
Positive topline results were announced from two Phase 3 clinical trials evaluating DFD-29.
Both trials achieved co-primary and all secondary endpoints over placebo and Oracea® with no significant safety issues.
The company plans to submit a New Drug Application to the FDA for DFD-29 in the second half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...